Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
ICI Confidential Report BL/B/2328
Heres what it means for Medicaid enrollees: Medicaid access through the BALANCE Model could begin as early as May 2026 States must opt in voluntarily its not automatic Participating states receive federally negotiated prices from Eli Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic) Wegovy and Zepbound starting doses would cost the program $350/month (reduced from over $1,000) Patients in participating states would pay $50/month for covered GLP-1s Prior authorization and qualifying criteria will still apply This is the biggest potential expansion of GLP-1 access for Medicaid enrollees in history but it depends on your state deciding to participate
The website uses browser cookies to improve user experience and secure transactions
The Role and Importance of GLP-1 Supporting Insulin Release After eating, GLP-1 signals the pancreas to release insulin
US$ 21.49
US$ 24.13
US$ 29.80
US$ 27.90
US$ 22.87
US$ 26.39
